Pfizer News Monitoring

400 Women Are Suing Pfizer Over Birth Control Shot That Allegedly Gave Them Brain Tumors

Image by Beata Zawrzel / NurPhoto via Getty / Futurism Recent research has linked Pfizer's widely-used Depo-Provera birth control shot to massively increased risk of developing brain tumors — and hundreds of women are suing the pharmaceutical …

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to …

Terrible News for Pfizer Stock Investors

The past three years have been challenging for Pfizer (PFE 0.11%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things …

STAT+: ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news

Adam Feuerstein/STAT Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by …

Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’

Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer

An experimental breast cancer drug from Arvinas and partner Pfizer modestly slowed disease progression in people whose tumors had changes to a specific gene, but did not provide a clear benefit to others who lacked that mutation. Full study results set to …

Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression

(Reuters) -An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca’s Faslodex in patients with a specific gene mutation, according to trial results announced on Saturday. The …

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …

#ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration with Acepodia and faces mounting lawsuits over its contraceptive, Depo-Provera. The decision to mutually terminate the partnership …

Advanced colon cancer patients lived twice as long with a Pfizer combo therapy, trial finds

A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial data published Friday in The New England Journal of Medicine and presented at the American Society of Clinical …

Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’

By Meg Tirrell, CNN (CNN) — Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu vaccine, claiming that “mRNA …

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

A precision oncology Pfizer drug now has clinical data showing it helped patients with colorectal cancer live longer, results that study investigators say could change the way physicians treat those whose disease exhibits the specific genetic signature …

ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ago, the company has now posted a phase 3 win that it hopes will …

Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%

Pfizer Inc. PFE on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for metastatic colorectal cancer (mCRC) …

ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC

Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of care (SOC) for metastatic colorectal cancer (mCRC) patients with BRAF V600E mutation. The company announced the survival …

This Week’s Biopharma News: Pfizer and Astellas Drug Improves Cancer Survival

HHS pulls Moderna flu funding   Moderna’s positive interim data from a phase I/II clinical study evaluating the safety and immunogenicity of its pandemic influenza vaccine, mRNA-1018, which it had expected to advance to late-stage development alongside …

#ASCO25: Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients

Pfizer and Arvinas gamble to shift breast cancer treatment paradigm

Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen receptor (ER) is expressed in most invasive BC cases (70 to 80%). Many therapies have therefore been developed to target this …

Luis M. Gallardo Launches the Meta Pets Method, A Playful Path to Transformation for Therapists, Coaches, and Educators

A Card-Based System for Self-Inquiry, Healing, and Awakening in Education, Coaching, and Therapy. MIAMI, FL, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- Author, hypnotherapist, and global well-being advocate Luis Miguel Gallardo announces …

Impelsys Strengthens AI Transformation Strategy with AlgoShack Partnership

NEW YORK, NY, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Impelsys, a global leader in technology solutions, is pleased to announce its strategic partnership with AlgoShack, a company that offers algoQA—a unified platform for end-to-end …

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“ …

TORRAS Personal Cooling with Coolify Series: A Tech-Driven Solution for Comfort, Wellness, and Women's Health

LOS ANGELES, June 01, 2025 (GLOBE NEWSWIRE) -- As global temperatures continue to rise and daily comfort becomes a growing concern, TORRAS is making waves with its innovative Coolify series—a wearable air conditioner engineered to deliver rapid, personal …

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in ...

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult …

Smile Scarsdale Family Dental Celebrates One Year of Smiles as Trusted Family Dentist in Scarsdale

SCARSDALE, NY, UNITED STATES, May 31, 2025 /⁨EINPresswire.com⁩/ -- Smile Scarsdale Family Dental is proud to celebrate its one-year anniversary of delivering exceptional family dental care to the Scarsdale community and surrounding areas. Since …

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/...

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at …

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated ...

Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% …

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 ...

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were …

Planet TV Studios Presents New Frontiers Episode 'Highlighting Emerging Technologies' Featuring Athena Clinic & Dr. ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON,, FL, UNITED STATES, May 31, 2025 …

Planet TV Studios Presents New Frontiers: Innovators Shaping Tomorrow. The content in the episode is a Planet TV Studios ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON, FL, UNITED STATES, May 31, 2025 …

'New Frontiers' Presents 4 Companies Revolutionizing: Brian Cancer Therapies, Robotic Surgery, Sustainable Solutions & ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON, FL, UNITED STATES, May 31, 2025 …

"New Frontiers" Presents Featuring Athena Clinic, MonDak Portables, LLC, NeOnc Technologies Holdings, Inc. & Hollobus ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON, FL, UNITED STATES, May 31, 2025 …

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-...

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large- …

San Francisco Dental Implant Center Announces New Content on Convenient Dental Implant Locations in SF

San Francisco Dental Implant Center, a top dental implant center in San Francisco, California, is proud to announce new content focusing on convenient location. SAN FRANCISCO, CA, UNITED STATES, May 31, 2025 /⁨EINPresswire.com⁩/ -- San Francisco …

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell ...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …

The Good Feet Store Opens in Seabrook, NH to Help Local Residents and Workforce Live the Life They Love

The Leading Retailer of Premium, Personally-Fitted Arch Supports Expands with the Tenth Store in the Boston Area SEABROOK, NH, UNITED STATES, May 30, 2025 /⁨EINPresswire.com⁩/ -- The Good Feet Store, recognized nationally as the market-leading …

Nurses for Natural Health Hosts Transformative Yoga Retreat for Nurses in France

PHOENIX , AZ, UNITED STATES, May 30, 2025 /⁨EINPresswire.com⁩/ -- This July, Nurses for Natural Health invites nurses from around the world to join a one-of-a-kind restorative yoga retreat in the picturesque town of Luz-Saint-Sauveur. Designed to …

Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec ...

L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1. L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer …